West Pharmaceutical Services, Inc. Q4 FY2025 earnings call

Management Statement and Operational Highlights

• 2025 Achievements: Surpassed $3,000,000,000 in net sales, achieved over 4% year-over-year organic growth, expanded operating margins, 8% adjusted EPS growth, and 70% free cash flow growth.
• Key Drivers: Growth fueled by biologics, biosimilars, Annex 1 regulatory requirements, and GLP-1 market. Long-term secular growth drivers include biologics, Annex 1, and GLP-1s.
• Product Launches: Launched West Synchrony prefillable syringe system, a fully verified platform for biologics.
• Business Divestiture: Sold SmartDose 3.5 mL business, aligning with customer development pipeline, closing mid-2026.
• Contract Manufacturing: Commenced commercial production in Dublin for drug handling, with the business ramping in 2026.
• Leadership: Strengthened executive team with 5 new members in the last 12 months, contributing to the organization.

Segment Performance

• Proprietary Product:
  • HVP components: Generated $390,000,000 in Q4, accounting for 48% of total net sales. Grew 15.1% organically in Q4 and 9% for the full year 2025. Driven by GLP-1 and non-GLP-1 recovery.
  • HVP delivery devices: $110,000,000 in Q4, 14% of sales. Down 18.1% organically year-on-year due to prior-year incentive fee, but some portfolio parts grew.
  • Standard products: $162,000,000 in Q4, 20% of business. Down 1.7% organically, with conversion to HVP components contributing.
• Contract Manufacturing: $143,000,000 in Q4, 1.9% organic growth. Commenced commercial production of drug handling at Dublin facility, ramping in 2026.

Guidance

• 2026 Outlook: Anticipates 5%-7% organic revenue growth and adjusted EPS midpoint of $8.025.
  • Proprietary segments: HVP components to drive high single-digit to low double-digit organic growth, HVP delivery devices to see mid single-digit growth post-SmartDose divestiture, Standard Products flat, Contract Manufacturing flat.
• Q1 2026: Expect revenue in range of $770,000,000-$790,000,000 (10%-13% reported growth, 5%-7% organic), and adjusted diluted EPS in range of $1.65-$1.70.

Risks

• Supply Chain Constraints: Demand outstripped supply in HVP components outside GLP-1, requiring capacity ramp-up.
• Regulatory Uncertainty: Impact of Annex 1 and other regulations on business operations and customer orders.
• Market Dynamics: Uncertainty in GLP-1 market growth, including oral vs injectable trends and potential cannibalization concerns.

Question and Answer

Q: Michael Leonidovich Ryskin with Bank of America asks about GLP-1 growth conservatism and capital deployment.

A: Eric M. Green and Robert McMahon respond that guidance is conservative, with confidence in non-GLP-1 growth offsetting potential GLP-1 flatness, and active consideration of capital deployment including M&A and share buybacks.

Q: Daniel Markowitz with Evercore inquires about high value components ex-GLP-1s in Q4 and capacity.

A: Eric M. Green and Robert McMahon discuss demand outstripping supply in non-GLP-1 HVP components, ongoing capacity expansion in Europe, and labor/equipment investments to meet demand.

Q: Justin D. Bowers with Deutsche Bank asks about new GLP-1 molecules and component usage.

A: Eric M. Green and Robert McMahon explain that new GLP-1 molecules use similar elastomeric components, with some requiring barrier coatings like FluroTec and NovaPure, and consistent win rates in biologics/biosimilars across geographies.

Q: Paul Richard Knight with KeyBanc asks about Grand Rapids and Dublin sites' ramp-up.

A: Eric M. Green and Robert McMahon detail Grand Rapids as more mature, while Dublin is in ramp-up for auto-injectors, multidose pens, and drug handling, with drug handling ramping in 2026-2027.

Q: Matthew Richard Larew with William Blair asks about device opportunity and Synchrony.

A: Eric M. Green explains that the device opportunity is a multiyear journey, with focus on line extensions, new formulations, and the launch of West Synchrony prefillable syringe, which has initial orders and is part of HVP spectrum expansion.